Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 7;10:496. doi: 10.3389/fphar.2019.00496

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Qin, Zhang, Yang, Li, Xu, Yao, Zhang, Gonzalez and Yao.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Effects of chemical inhibitors Ko143 (5 and 20 μM) and MK571 (5 and 20 μM) on the formation and efflux excretion of fraxetin-O-glucuronides in HeLa1A9 cells. (A) Effects of Ko143 (5 and 20 μM) and MK571 (5 and 20 μM) on the accumulation of fraxetin-8-O-glucuronide (G1) in the extracellular medium. (B) effects of Ko143 (5 and 20 μM) and MK571 (5 and 20 μM) on fraxetin-7-O-glucuronide (G2) excretion into extracellular solutions. (C) the influence of Ko143 (5 and 20 μM) and MK571 (5 and 20 μM) on the efflux excretion rates of G1 and G2. (D) effects of Ko143 (5 and 20 μM) and MK571 (5 and 20 μM) on the intracellular G1 and G2 levels. (E) the influence of Ko143 (5 and 20 μM) and MK571 (5 and 20 μM) on the fraction metabolized (f_met) of fraxetin; Data are presented as mean ± SD. ^∗,#p < 0.05, ^∗∗,##p < 0.01, and ^{∗∗∗,###}p < 0.001 as compared with the control.